Published in Int Arch Allergy Appl Immunol on January 01, 1969
Glomerular deposition of properdin in acute and chronic glomerulonephritis with hypocomplementemia. J Clin Invest (1971) 3.06
Complement studies in membrano-proliferative glomerulonephritis. Clin Exp Immunol (1972) 2.60
Properdin anc C3 proactivator: alternate pathway components in human glomerulonephritis. J Clin Invest (1973) 2.33
Evidence for complement activation via the alternate pathway in skin diseases, I. Herpes gestationis, systemic lupus erythematosus, and bullous pemphigoid. J Clin Invest (1973) 1.73
C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase. J Clin Invest (1976) 1.38
Hypocomplementemia of membranoproliferative nephritis. Dependence of the nephritic factor reaction on properdin factor B. J Clin Invest (1973) 1.35
Post-streptococcal acute glomerulonephritis in children: clinical features and pathogenesis. Pediatr Nephrol (2010) 1.11
Metabolism of properdin in normal subjects and patients with renal disease. J Clin Invest (1975) 1.09
Humoral immune system in inflammatory bowel disease: I. Complement levels. Gut (1977) 1.05
Relative importance of C3b inactivator and beta 1H globulin in the modulation of the properdin amplification loop in systemic lupus erythematosus. Clin Exp Immunol (1979) 0.96
Complement and the kidney. Proc R Soc Med (1972) 0.91
Complement inhibitors and immunoconglutinins in ulcerative colitis and Crohn's disease. Gut (1980) 0.90
Clinical and immunological studies in a case of selective complete C1q deficiency. Clin Exp Immunol (1979) 0.88
Evaluation of alternative pathway and factor B haemolytic activities in patients with systemic lupus erythematosus: correlations with the alternative pathway regulatory proteins. Clin Exp Immunol (1980) 0.84
Relative importance of C4 binding protein in the modulation of the classical pathway C3 convertase in patients with systemic lupus erythematosus. Clin Exp Immunol (1983) 0.79
Role of properdin in kidney diseases. Calif Med (1972) 0.75
In vitro bactericidal capacity of human polymorphonuclear leukocytes: diminished activity in chronic granulomatous disease of childhood. J Clin Invest (1967) 10.26
Studies of the metabolic activity of leukocytes from patients with a genetic abnormality of phagocytic function. J Clin Invest (1967) 9.01
Physical, chemical, and immunological properties of lipopolysaccharide released from Escherichia coli by ethylenediaminetetraacetate. J Biol Chem (1968) 7.13
Evolutionary conservation of surface molecules that distinguish T lymphocyte helper/inducer and cytotoxic/suppressor subpopulations in mouse and man. J Exp Med (1981) 6.82
Specific receptor sites for chemotactic peptides on human polymorphonuclear leukocytes. Proc Natl Acad Sci U S A (1977) 5.87
Suppressor cell activity after concanavalin A treatment of lymphocytes from normal donors. J Exp Med (1976) 5.50
Stimulation of rheumatoid synovial cell collagenase and prostaglandin production by partially purified lymphocyte-activating factor (interleukin 1). Proc Natl Acad Sci U S A (1981) 4.89
Acute poststreptococcal glomerulonephritis: immune deposit disease. J Clin Invest (1966) 4.64
Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet (1968) 4.41
Thymus-dependent membrane antigens in man: inhibition of cell-mediated lympholysis by monoclonal antibodies to TH2 antigen. Proc Natl Acad Sci U S A (1981) 4.38
Human mononuclear leukocyte chemotaxis: a quantitative assay for humoral and cellular chemotactic factors. J Immunol (1972) 4.38
Effect of virus infections on the function of the immune system. Annu Rev Microbiol (1970) 4.30
Interactions of the complement system with endotoxic lipopolysaccharide: consumption of each of the six terminal complement components. J Exp Med (1968) 4.19
The functions of the thymus system and the bursa system in the chicken. J Exp Med (1966) 4.07
Fatal granulomatous disease of childhood. An inborn abnormality of phagocytic function. Lancet (1966) 3.97
The IgA system. I. Studies of the transport and immunochemistry of IgA in the saliva. J Exp Med (1966) 3.97
Primary immunodeficiencies. Report of a World Health Organization Committee. Pediatrics (1971) 3.69
Chemotactic and anaphylatoxic fragment cleaved from the fifth component of guinea pig complement. Science (1968) 3.69
Wiskott-Aldrich syndrome. An immunologic deficiency disease involving the afferent limb of immunity. Am J Med (1968) 3.54
Macrophages as a source of tumoricidal activity (tumor-necrotizing factor). Infect Immun (1980) 3.41
Interactions of the complement system with endotoxic lipopolysaccharide. Generation of a factor chemotactic for polymorphonuclear leukocytes. J Exp Med (1968) 3.33
Inhibition of lymphocyte proliferation by a synthetic peptide homologous to retroviral envelope proteins. Science (1985) 3.27
rac, a novel ras-related family of proteins that are botulinum toxin substrates. J Biol Chem (1989) 3.21
Characterization of C-reactive protein and the complement subcomponent C1t as homologous proteins displaying cyclic pentameric symmetry (pentraxins). Proc Natl Acad Sci U S A (1977) 3.13
Protection of phagocytized bacteria from the killing action of antibiotics. Nature (1966) 3.12
Educating future physicians for Ontario. Acad Med (1998) 3.06
Collagenase production by endotoxin-activated macrophages. Proc Natl Acad Sci U S A (1974) 3.05
The chemotactic attraction of human fibroblasts to a lymphocyte-derived factor. J Exp Med (1976) 3.04
Polymorphonuclear leukocyte chemotactic activity in rabbit serum and Guinea pig serum treated with immune complexes: evidence for c5a as the major chemotactic factor. Infect Immun (1970) 3.01
Bone resorbing activity in supernatant fluid from cultured human peripheral blood leukocytes. Science (1972) 2.91
Identification of a p69,71 complex expressed on human T cells sharing determinants with B-type chronic lymphatic leukemic cells. J Exp Med (1980) 2.89
Interactions of the complement system with the surface and endotoxic lipopolysaccharide of Veillonella alcalescens. J Exp Med (1967) 2.87
Reaction of a cobra venom factor with guinea pig complement and generation of an activity chemotactic for polymorphonuclear leukocytes. Proc Soc Exp Biol Med (1969) 2.76
Complement activity and inflammatory neutrophil exudation in man. Studies in patients with glomerulonephritis, essential hypocomplementemia and agammaglobulinemia. Int Arch Allergy Appl Immunol (1967) 2.64
Collagenase production by lymphokine-activated macrophages. Science (1975) 2.64
Electron microscopic localization of endotoxic lipopolysaccharide in gram-negative organisms. Ann N Y Acad Sci (1966) 2.61
Identification of beta-adrenergic receptors in human lymphocytes by (-) (3H) alprenolol binding. J Clin Invest (1976) 2.58
Inflammatory and immunomodulatory roles of TGF-beta. Immunol Today (1989) 2.56
A neutrophil chemotatic factor derived from C'5 upon interaction of guinea pig serum with endotoxin. J Immunol (1969) 2.54
A potential second messenger role for unsaturated fatty acids: activation of Ca2+-dependent protein kinase. Science (1984) 2.53
The cellular immune defect in chronic mucocutaneous candidiasis. Lancet (1969) 2.53
C2 deficiency. Development of lupus erythematosus. J Clin Invest (1973) 2.52
Neisseria meningitidis and Neisseria gonorrhoeae bacteremia associated with C6, C7, or C8 deficiency. Ann Intern Med (1979) 2.51
Interactions of C-reactive protein with the complement system. I. Protamine-induced consumption of complement in acute phase sera. J Exp Med (1974) 2.47
A newly defined X-linked trait in man with demonstration of the Lyon effect in carrier females. Lancet (1967) 2.47
Influence of diet on survival of mice. Proc Natl Acad Sci U S A (1976) 2.45
An NK1.1+ CD4+8- single-positive thymocyte subpopulation that expresses a highly skewed T-cell antigen receptor V beta family. Proc Natl Acad Sci U S A (1992) 2.43
Deficient immunologic functions of NZB mice. Proc Soc Exp Biol Med (1968) 2.41
Macrophage activation by mycobacterial water soluble compounds and synthetic muramyl dipeptide. J Immunol (1979) 2.39
Neoantigen of the polymerized ninth component of complement. Characterization of a monoclonal antibody and immunohistochemical localization in renal disease. J Clin Invest (1983) 2.39
The complement profile in acute glomerulonephritis systemic lupus erythematosus and hypocomplementemic chronic glomerulonephritis. Contrasts and experimental correlations. Int Arch Allergy Appl Immunol (1968) 2.38
Effects of protein insufficiency on immune responsiveness. Am J Clin Nutr (1974) 2.37
Localization of immunological complexes fixing beta1C (C3) in germinal centers of lymph nodes. J Exp Med (1969) 2.36
Chemical suppression of adaptive immunity. Adv Immunol (1967) 2.35
Calcium influx requirement for human neutrophil chemotaxis: inhibition by lanthanum chloride. Science (1976) 2.34
Growth of a pure population of mouse mast cells in vitro with conditioned medium derived from concanavalin A-stimulated splenocytes. Proc Natl Acad Sci U S A (1981) 2.33
NK1.1+ CD4+ CD8- thymocytes with specific lymphokine secretion. Eur J Immunol (1993) 2.32
An inherited abnormality of neutrophil adhesion. Its genetic transmission and its association with a missing protein. N Engl J Med (1980) 2.32
Effect of antibiotics on the bactericidal activity of human leukocytes. J Lab Clin Med (1968) 2.31
Occurrence of malignancy in immunodeficiency diseases. A literature review. Cancer (1971) 2.31
T-cell depletion of HLA-identical transplants in leukemia. Blood (1991) 2.25
C-reactive protein and the acute phase response. Adv Intern Med (1982) 2.20
Setting educational priorities for learning the concepts of population health. Med Educ (1989) 2.19
A human mononuclear leukocyte chemotactic factor: characterization, specificity and kinetics of production by homologous leukocytes. J Immunol (1973) 2.18
A chemotactic factor for mononuclear leukocytes. Proc Soc Exp Biol Med (1971) 2.18
Significance of complement to the mechanism of action of endotoxin. Curr Top Microbiol Immunol (1969) 2.18
C-reactive protein is protective against Streptococcus pneumoniae infection in mice. J Exp Med (1981) 2.17
Effects on C-reactive protein on the lymphoid system. I. Binding to thymus-dependent lymphocytes and alteration of their functions. J Exp Med (1975) 2.17
Monoclonal antibody analysis of human T lymphocyte subpopulations exhibiting autologous mixed lymphocyte reaction. Proc Natl Acad Sci U S A (1981) 2.16
Biological activity of complement in vivo. Role of C5 in the accumulation of polymorphonuclear leukocytes in inflammatory exudates. J Exp Med (1971) 2.15
Combined immunodeficiency disease associated with adenosine deaminase deficiency. Report on a workshop held in Albany, New York, October 1, 1973. J Pediatr (1975) 2.15
Suppression of B-cell differentiation by leukocytes from hypogammaglobulinemic patients. J Clin Invest (1976) 2.15
Generation and characterization of a lipopolysaccharide-induced and serum-derived cytotoxic factor for tumor cells. Infect Immun (1980) 2.12
Improved tests for the evaluation of neutrophil function in human disease. J Lab Clin Med (1968) 2.11
A mammalian equivalent of the avian bursa of Fabricius. Lancet (1966) 2.11
Depression of macrophage function by a factor produced by neoplasms: a merchanism for abrogation of immune surveillance. J Immunol (1976) 2.11
The primary role of lymphoreticular cells in the mediation of host responses to bacterial endotoxim. J Infect Dis (1980) 2.11
Molecular and cellular mechanisms of leukocyte chemotaxis. Science (1981) 2.07
Development and function of the immunoglobulin producing system. I. Effect of bursectomy at different stages of development on germinal centers, plasma cells, immunoglobulins and antibody production. Int Arch Allergy Appl Immunol (1969) 2.06
Kaposi's sarcoma: a review and recent developments. CA Cancer J Clin (1981) 2.05
Ubiquitin-dependent degradation of IkappaBalpha is mediated by a ubiquitin ligase Skp1/Cul 1/F-box protein FWD1. Proc Natl Acad Sci U S A (1999) 2.04
Development of "autoimmune processes" in rabbits after neonatal removal of central lymphoid tissue. Lancet (1965) 2.04
Influence of the human T-lymphotropic virus/lymphadenopathy-associated virus on functions of human lymphocytes: evidence for immunosuppressive effects and polyclonal B-cell activation by banded viral preparations. Proc Natl Acad Sci U S A (1985) 2.04